Printer Friendly

Cardiac Science Receives Regulatory Approval to Market Powerheart in Australia; Company Announces Australian Distribution Partner and $333,000 Order of Powerhearts.

Business Editors, Health/Medical Writers

BIOWIRE2K

IRVINE, Calif.--(BW HealthWire)--Dec. 27, 2000

Cardiac Science Inc., (Nasdaq:DFIB), today announced that it has been granted approval by the Australian Therapeutic Goods Administration to allow Cardiac Science to begin marketing its unique fully automatic Powerheart(R) hospital bedside defibrillator-monitor in Australia.

Cardiac Science also announced it entered into an exclusive distribution agreement for Australia and sold 50 of its Powerheart defibrillator-monitors along with disposable defibrillation electrodes and related accessories resulting in $333,500 in revenue.

"With over 1,200 hospitals in Australia, we believe there is a substantial market for Powerheart," said Ray Jarvis, sales and marketing manager for Cardiac Science's new Australian distribution partner, CS Australia Pty Ltd of Melbourne, Australia. "Our marketing plan is to offer Powerheart to Australian hospitals without the hospital incurring any capital equipment cost for the Powerheart device itself. Since hospitals will incur only the cost of prophylactically-attached disposable electrodes that are replaced daily, we believe we can significantly accelerate the adoption rate of Powerheart in Australia while generating a healthy return for our distribution company."

Cardiovascular disease is Australia's largest health problem with over 52,000 deaths in 1998 alone. Moreover, each year it is estimated that over 30,000 Australians undergo heart surgery that put them at risk of developing life-threatening heart rhythms. Australia has a population of approximately 18 million and spends approximately $27 billion, or 8.5 percent of its gross domestic product on healthcare services of which 70 percent of this expenditure is publicly funded.

About Australian Therapeutic Goods Administration

Australian Therapeutic Goods Administration ("TGA"), the Australian medical products regulatory authority, acts independently of the U.S. Food and Drug Administration. FDA approval alone does not qualify a medical device for importation into Australia. Before medical devices can be legally supplied in Australia, a device is subject to rigorous review and must be registered in the Australian Register of Therapeutic Goods. Manufacturers are required to provide evidence to establish quality, safety and efficacy of their device, as well as the standard of manufacture of the goods, for review by TGA prior to approval.

About Cardiac Science

Cardiac Science develops and markets life-saving external cardiac defibrillator devices and proprietary software that monitors a patient's cardiac activity, instantly detects the onset of a life-threatening heart rhythm and automatically delivers defibrillation shocks within as little as 10 seconds and without human intervention to re-establish the heart's normal rhythm. Its core proprietary defibrillation and electrode technology platform has multiple applications, including use in external and wearable defibrillators and with standard patient monitors widely used in hospitals throughout the world. The growth of the company's installed base provides a recurring revenue stream from the sale of proprietary disposable defibrillator electrodes.

On Nov. 27, 2000 Cardiac Science announced that it offered to acquire all of the outstanding common stock of Spacelabs Medical Inc. (Nasdaq:SLMD) for $15 per share. Cardiac Science is aggressively pursuing all avenues in its effort to acquire Spacelabs in a negotiated transaction.

Cardiac Science began marketing its first commercial product, the Powerheart in early 2000. For more information on Cardiac Science, please visit its Internet site at www.cardiacscience.com.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Such forward-looking statements include, but are not limited to: the size of the market for Powerheart in Australia; the life-saving potential of Cardiac Science's technology; the Company's ability to integrate its technology into patient monitors, develop new products and improve patient-care; a potential transaction between Cardiac Science Inc. and Spacelabs Medical, Inc. that may or may not occur. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company's Form 10-K for the year ending December 31, 1999 and other documents filed with the Securities and Exchange Commission.
COPYRIGHT 2000 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Dec 27, 2000
Words:690
Previous Article:Microtest, Inc. and Business Communications Services Form Alliance; Cabletesting.com to Feature Industry-Leading Cabling Standards Report.
Next Article:World Wide Wireless Communications Announces Appointment of New Chief Operating Officer.
Topics:


Related Articles
Cardiac Science Announces First Quarter 2000 Results; $625,000 of Powerheart Hospital Bedside Defibrillator-Monitors Sold.
Cardiac Science Announces Existing Shareholders to Invest Additional Capital.
First Life Saved by Cardiac Science's Unique Hospital Defibrillator.
AUSTRALIA APPROVES CARDIAC SCIENCES' POWERHEART.
Albert Ashforth launches defibrillator program.
Remaking the world in our own image: Australia's efforts to liberalize trade in education services.
GENEPHARM BEGINS REGISTRATION OF FIVE ANTI-CANCER DRUGS.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters